Autopsy and Case Reports
Autopsy and Case Reports
Article / Clinical Case Report

Plasmacytoid urothelial carcinoma: a case of histological variant of urinary bladder cancer with aggressive behavior

Leonardo Gomes da Fonseca; Ciro Eduardo Souza; Romulo Loss Mattedi; Daniel Motta Girardi; Álvaro Sadek Sarkis; Paulo Marcelo Gem Hoff

Downloads: 6
Views: 540


Plasmocytoid variant urothelial carcinoma (PVUC) of the urinary bladder is a rare histological variant of transitional cell carcinoma. Data regarding PVUC shows that this neoplasia presents a distinctive clinical outcome represented by aggressive behavior and poor survival rate. The authors report a case of a 57-year-old male patient with a 3-month history of hematuria and pelvic pain. Radical cystectomy with lymphadenectomy was performed and pathological examination showed a pT3pN0 PVUC of the bladder. The patient remained free of recurrence for 8 months, but the disease recurred involving the abdominal wall and subcutaneous tissue. Chemotherapy provided a positive clinical response and relief of symptoms. The authors call attention to the aggressiveness of this rare variant of bladder cancer and recommend radical surgery and multidisciplinary management of this neoplasm.


Carcinoma, Urothelium, Urinary Bladder Neoplasms, Cystectomy


Sahin AA, Myhre M, Ro JY, Sneige N, Dekmezian RH, Ayala AG. Plasmacytoid transitional cell carcinoma. Report of a case with initial presentation mimicking multiple myeloma. Acta Cytol. 1991;35(3):277-80. [PMID:1710402].

Keck B, Stoehr R, Wach S, et al. The plasmacytoid carcinoma of the bladder—rare variant of aggressive urothelial carcinoma. Int J Cancer. 2011;129(2):346-54. []. [PMID:20878954]

Dayyani F, Czerniak BA, Sircar K, et al. Plasmacytoid urothelial carcinoma, a chemosensitive cancer with poor prognosis, and peritoneal carcinomatosis. J Urol. 2013;189(5):1656-61. []. [PMID:23159581]

Mai KT, Park PC, Yazdi HM, et al. Plasmacytoid urothelial carcinoma of the urinary bladder report of seven new cases. Eur Urol. 2006;50(5):1111-4. []. [PMID:16626859]

Lopez-Beltran A, Requena MJ, Montironi R, Blanca A, Cheng L. Plasmacytoid urothelial carcinoma of the bladder. Hum Pathol. 2009;40(7):1023-8. []. [PMID:19297008]

Raspollini MR, Sardi I, Giunti L, et al. Plasmacytoid urothelial carcinoma of the urinary bladder: clinicopathologic, immunohistochemical, ultrastructural, and molecular analysis of a case series. Hum Pathol. 2011;42(8):1149-58. []. [PMID:21334719]

Erdemir F, Ozcan F, Kilicaslan I, Parlaktas BS, Uluocak N, Gokce O. The relationship between the expression of E-cadherin and tumor recurrence and progression in high-grade stage T1 bladder urothelial carcinoma. Int Urol Nephrol. 2007;39(4):1031-7. []. [PMID:17340210]

Paner GP, Annaiah C, Gulmann C, et al. Immunohistochemical evaluation of novel and traditional markers associated with urothelial differentiation in a spectrum of variants of urothelial carcinoma of the urinary bladder. Hum Pathol. 2014;45(7):1473-82. []. [PMID:24780825]

Kaimakliotis HZ, Monn MF, Cheng L, et al. Plasmacytoid bladder cancer: variant histology with aggressive behavior and a new mode of invasion along fascial planes. Urology. 2014;83(5):1112-6. []. [PMID:24582117]

Porten SP, Willis D, Kamat AM. Variant histology: role in management and prognosis of nonmuscle invasive bladder cancer. Curr Opin Urol. 2014;24(5):517-23. []. [PMID:24921905]

Kaimakliotis HZ, Monn MF, Cary KC, et al. Plasmacytoid variant urothelial bladder cancer: is it time to update the treatment paradigm? Urol Oncol. 2014;32(6):833-8. []. [PMID:24954925]

Loehrer PJ Sr, Einhorn LH, Elson PJ, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol. 1992;10(7):1066-73. [PMID:1607913].


Publication date:

569696b864cc8b5cda711c0d autopsy Articles

Autops Case Rep

Share this page
Page Sections